MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to ...

Randomization monitoring is a type of statistical/central monitoring, which ICH notes should be performed by appropriately ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...

If the future of oncology research is to be inclusive, efficient, and representative, community-based clinical trials must be ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can ...